0001193125-17-241556.txt : 20170731 0001193125-17-241556.hdr.sgml : 20170731 20170731090134 ACCESSION NUMBER: 0001193125-17-241556 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170731 DATE AS OF CHANGE: 20170731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-210876 FILM NUMBER: 17991658 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 RW 1 d433506drw.htm RW RW

Nexvet Biopharma plc

Unit 5, Sragh Technology Park

Rahan Road, Tullamore

Co. Offaly, R35 FR98, Ireland

By EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3628

 

  Re:  

Nexvet Biopharma public limited company

Registration Statement on Form S-3 (File No. 333-210876)

Ladies and Gentlemen:

Nexvet Biopharma public limited company (the “Company”) hereby makes application to withdraw the Registration Statement on Form S–3 originally filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) on April 22, 2016 and amended on May 3, 2016 (Registration No. 333-210876) (the “Registration Statement”), effective immediately.

The Registration Statement is being withdrawn because, on July 31, 2017, the Company was acquired by Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis Inc. (the “Acquisition”) pursuant to a “scheme of arrangement” under Irish law. In connection with the Acquisition, the Company has determined that the Registration Statement is unnecessary and that it is in the Company’s best interest to withdraw the Registration Statement. No securities have been sold pursuant to the Registration Statement.

The Company requests that the Commission consent to this application on the grounds that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors as contemplated by Rule 477(a) under the Securities Act of 1933, as amended.

Please provide a copy of the order consenting to the withdrawal of the Registration Statement to Andrew Ledbetter of DLA Piper LLP (US) (“DLA Piper”), counsel to the Company, via email at andrew.ledbetter@dlapiper.com or via facsimile at 206-494-1800. If you have any questions with respect to this matter, please contact Andrew Ledbetter of DLA Piper at (206) 839-4845.

Sincerely,

 

Nexvet Biopharma public limited company

By:   /s/ Damian Lismore
Name:   Damian Lismore
Title:   Authorized officer

cc: Andrew Ledbetter (DLA Piper)